# NPC-12G Gel 0.2% Sirolimus PK Bridging Study

> **NCT03972462** · PHASE1 · COMPLETED · sponsor: **Nobelpharma** · enrollment: 12 (actual)

## Conditions studied

- Bioavailability Study

## Interventions

- **DRUG:** NPC-12G Gel 0.2%
- **DRUG:** Rapamune® 2 mg tablet

## Key facts

- **NCT ID:** NCT03972462
- **Lead sponsor:** Nobelpharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-31
- **Primary completion:** 2019-06-17
- **Final completion:** 2019-06-17
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03972462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03972462, "NPC-12G Gel 0.2% Sirolimus PK Bridging Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03972462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*